
|Articles|October 1, 2002
Commitment to R&D strengthens Allergan product pipeline
Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
Inside the clinic: Surgeon shares real-world experience
3
What changed in glaucoma care in 2025: Surgeon perspective
4
FDA approvals in 2025: What changed and why it matters for ophthalmologists
5












































